7.6(top 2%)
impact factor
1.5K(top 20%)
papers
35.9K(top 10%)
citations
77(top 10%)
h-index
7.8(top 2%)
impact factor
1.6K
all documents
40.1K
doc citations
117(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1‘Acute myeloid leukemia: a comprehensive review and 2016 update’Blood Cancer Journal2016885
2CAR-T cell therapy: current limitations and potential strategiesBlood Cancer Journal2021871
3Acute lymphoblastic leukemia: a comprehensive review and 2017 updateBlood Cancer Journal2017757
4The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussionBlood Cancer Journal2018404
5Acute myeloid leukemia: current progress and future directionsBlood Cancer Journal2021313
6Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemiaBlood Cancer Journal2014254
7Pathogenesis of bone disease in multiple myeloma: from bench to bedsideBlood Cancer Journal2018219
8Acute promyelocytic leukemia: where did we start, where are we now, and the futureBlood Cancer Journal2015211
9Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsBlood Cancer Journal2015190
10Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemiaBlood Cancer Journal2015188
11Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blastsBlood Cancer Journal2016181
12Multiple myeloma current treatment algorithmsBlood Cancer Journal2020178
13Current status of autologous stem cell transplantation for multiple myelomaBlood Cancer Journal2019175
14Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaBlood Cancer Journal2018171
15Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studyBlood Cancer Journal2019171
16Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingBlood Cancer Journal2018170
17Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4Blood Cancer Journal2015166
18High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sitesBlood Cancer Journal2013164
19Interpretation of cytogenetic results in multiple myeloma for clinical practiceBlood Cancer Journal2015163
20Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directionsBlood Cancer Journal2017161
21Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicingBlood Cancer Journal2012149
22Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an updateBlood Cancer Journal2011142
23Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patientsBlood Cancer Journal2014142
24CircRNAs in hematopoiesis and hematological malignanciesBlood Cancer Journal2016139
25Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaBlood Cancer Journal2020137
26High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myelomaBlood Cancer Journal2017132
27Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)Blood Cancer Journal2020131
28TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolutionBlood Cancer Journal2015130
29PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survivalBlood Cancer Journal2015129
30International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)Blood Cancer Journal2020126
31PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantationBlood Cancer Journal2015124
32Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working GroupBlood Cancer Journal2017124
33Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balanceBlood Cancer Journal2013118
34An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategiesBlood Cancer Journal2015117
35Myeloma cells suppress osteoblasts through sclerostin secretionBlood Cancer Journal2011113
36Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblastsBlood Cancer Journal2018113
37CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatmentBlood Cancer Journal2017108
38Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutationsBlood Cancer Journal2012107
39Myelodysplastic syndromes current treatment algorithm 2018Blood Cancer Journal2018107
40The role of epigenetics in the biology of multiple myelomaBlood Cancer Journal2014106
41Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignanciesBlood Cancer Journal2021106
42Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasoneBlood Cancer Journal2019104
43The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatmentBlood Cancer Journal2021103
44Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaBlood Cancer Journal2016102
45Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomibBlood Cancer Journal2015101
46Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaBlood Cancer Journal2016101
47Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemiaBlood Cancer Journal2020101
48A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphomaBlood Cancer Journal2015100
49Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisBlood Cancer Journal2015100
50Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemiaBlood Cancer Journal2021100